Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia

Expert Opin Investig Drugs. 2024 Nov;33(11):1099-1102. doi: 10.1080/13543784.2024.2414126. Epub 2024 Oct 9.
No abstract available

Keywords: APOC3; ApoC-III; apoC-III inhibitor; hypertriglyceridemia; plozasiran; siRNA; triglyceride.

Publication types

  • Editorial